Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bielski, M.; Yomtovian, R.; Lazarus, H.M.; Rosenthal, N. Prolonged Isolated Thrombocytopenia after Hematopoietic Stem Cell Transplantation: Morphologic Correlation. Bone Marrow Transpl. 1998, 22, 1071–1076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stanworth, S.J.; Estcourt, L.J.; Powter, G.; Kahan, B.C.; Dyer, C.; Choo, L.; Bakrania, L.; Llewelyn, C.; Littlewood, T.; Soutar, R.; et al. A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. N. Engl. J. Med. 2013, 368, 1771–1780. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ministry of Health, Labour and Welfare; Pharmaceutical Safety and Environmental Health Bureau. Guidelines for the Use of Blood Products. Available online: https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000161115.pdf (accessed on 8 December 2020).
- Tsukimoto, I. Present Status and Future Aspects of Transfusion Therapy in Children. Jpn. J. Pediatr. Hematol. 1993, 7, 177–186. [Google Scholar]
- Cheng, G.; Saleh, M.N.; Marcher, C.; Vasey, S.; Mayer, B.; Aivado, M.; Arning, M.; Stone, N.L.; Bussel, J.B. Eltrombopag for Management of Chronic Immune Thrombocytopenia (RAISE): A 6-Month, Randomised, Phase 3 Study. Lancet 2011, 377, 393–402. [Google Scholar] [CrossRef]
- Olnes, M.J.; Scheinberg, P.; Calvo, K.R.; Desmond, R.; Tang, Y.; Dumitriu, B.; Parikh, A.R.; Soto, S.; Biancotto, A.; Feng, X.; et al. Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. N. Engl. J. Med. 2012, 367, 11–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanaka, T.; Inamoto, Y.; Yamashita, T.; Fuji, S.; Okinaka, K.; Kurosawa, S.; Kim, S.W.; Tanosaki, R.; Fukuda, T. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol. Blood Marrow Transpl. 2016, 22, 919–924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fu, H.; Zhang, X.; Han, T.; Mo, X.; Wang, Y.; Chen, H.; Han, W.; Wang, J.; Wang, F.; Yan, C.; et al. Eltrombopag Is an Effective and Safe Therapy for Refractory Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation. Bone Marrow Transpl. 2019, 54, 1310–1318. [Google Scholar] [CrossRef] [PubMed]
- Yuan, C.; Boyd, A.M.; Nelson, J.; Patel, R.D.; Varela, J.C.; Goldstein, S.C.; Ahmad, S.; Zhu, X.; Mori, S. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Biol. Blood Marrow Transpl. 2019, 25, 1320–1324. [Google Scholar] [CrossRef] [PubMed]
- Samarkandi, H.; Al Nahedh, M.; Alfattani, A.; Alsharif, F.; Bakshi, N.; Rasheed, W.; Alfraih, F.; Alhumaid, M.; Alkhudair, N.; Alhayli, S.; et al. Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation: Rertrospective Observational Trial. Hematol. Oncol. Stem Cell Ther. 2020; in press. [Google Scholar] [CrossRef] [PubMed]
- Rivera, D.; Bastida, J.M.; Lopez-Corral, L.; Sanchez-Guijo, F.; Cabrero, M.; Martin, A.; Perez, E.; Lopez-Parra, M.; Avendaño, A.; Veiga, A.; et al. Usefulness of Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Bone Marrow Transpl. 2019, 54, 757–761. [Google Scholar] [CrossRef] [PubMed]
- Mahat, U.; Rotz, S.J.; Hanna, R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transpl. 2020, 26, e65–e73. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.H.; Zhou, S.; Feng, F.; Han, W.; Chen, H.; Xu, L.; Huang, X.J. Prolonged Isolated Thrombocytopenia (PIT) Is Associated with Platelet Aggregation, Which Is Affected by Endothelial Progenitor Cells (EPCs) Following Allo-HSCT. Blood 2014, 124, 2513. [Google Scholar] [CrossRef]
- Naithani, R.; Sachdev, M.; Uttam, R. Successful Use of Eltrombopag in a Child with Hurler Syndrome after Haploidentical Hematopoietic Stem Cell Transplantation. J. Pediatr. Hematol. Oncol. 2016, 38, 163–164. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Wu, R.; Wang, B.; Fu, L.; Zhu, G.; Zhou, X.; Ma, J.; Zhang, L.; Qin, M. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children. J. Pediatr. Hematol. Oncol. 2019, 41, 38–41. [Google Scholar] [CrossRef] [PubMed]
- Yaman, Y.; Elli, M.; Şahin, Ş.; Özdilli, K.; Bilgen, H.; Bayram, N.; Nepesov, S.; Anak, S. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation in Children: Single-Centre Experience. Pediatr. Transpl. 2021, e13962. [Google Scholar] [CrossRef] [PubMed]
- Nishikawa, S.; Arai, S.; Masamoto, Y.; Kagoya, Y.; Toya, T.; Watanabe-Okochi, N.; Kurokawa, M. Thrombopoietin/MPL Signaling Confers Growth and Survival Capacity to CD41-Positive Cells in a Mouse Model of Evi1 Leukemia. Blood 2014, 124, 3587–3596. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bussel, J.B.; de Miguel, P.G.; Despotovic, J.M.; Grainger, J.D.; Sevilla, J.; Blanchette, V.S.; Krishnamurti, L.; Connor, P.; David, M.; Boayue, K.B.; et al. Eltrombopag for the Treatment of Children with Persistent and Chronic Immune Thrombocytopenia (PETIT): A Randomised, Multicentre, Placebo-Controlled Study. Lancet Haematol. 2015, 2, e315–e325. [Google Scholar] [CrossRef]
- Grainger, J.D.; Locatelli, F.; Chotsampancharoen, T.; Donyush, E.; Pongtanakul, B.; Komvilaisak, P.; Sosothikul, D.; Drelichman, G.; Sirachainan, N.; Holzhauer, S.; et al. Eltrombopag for Children with Chronic Immune Thrombocytopenia (PETIT2): A Randomised, Multicentre, Placebo-Controlled Trial. Lancet 2015, 386, 1649–1658. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Matsumoto, M.; Terada, K.; Tsuchimochi, T.; Takahashi, S.; Noguchi, Y.; Igarashi, S. Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia. Hematol. Rep. 2022, 14, 240-244. https://doi.org/10.3390/hematolrep14030033
Matsumoto M, Terada K, Tsuchimochi T, Takahashi S, Noguchi Y, Igarashi S. Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia. Hematology Reports. 2022; 14(3):240-244. https://doi.org/10.3390/hematolrep14030033
Chicago/Turabian StyleMatsumoto, Megumi, Kazuki Terada, Taichiro Tsuchimochi, Satoko Takahashi, Yasushi Noguchi, and Shunji Igarashi. 2022. "Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia" Hematology Reports 14, no. 3: 240-244. https://doi.org/10.3390/hematolrep14030033
APA StyleMatsumoto, M., Terada, K., Tsuchimochi, T., Takahashi, S., Noguchi, Y., & Igarashi, S. (2022). Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia. Hematology Reports, 14(3), 240-244. https://doi.org/10.3390/hematolrep14030033